Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data

Abstract We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)—standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Ca...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Akira Shinohara, Yuki Takumoto, Junko Tauchi, Koki Morishita, Toshikatsu Kawasaki, Manabu Akazawa
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2025-01-01
Serie:	Scientific Reports
Soggetti:	Gemcitabine plus nab-paclitaxel Modified FOLFIRINOX Pancreatic cancer Chemotherapy Cost-effectiveness
Accesso online:	https://doi.org/10.1038/s41598-024-80549-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!